Copyright
©The Author(s) 2016.
World J Meta-Anal. Oct 26, 2016; 4(5): 105-117
Published online Oct 26, 2016. doi: 10.13105/wjma.v4.i5.105
Published online Oct 26, 2016. doi: 10.13105/wjma.v4.i5.105
Table 6 Summary of prognostic factors presented in relevant clinical trials
| Ref. | Year | Prognostic factors for response | Prognostic factors for TTLP | Prognostic factors for PFS | Prognostic factors for OS |
| Olofsson et al[55] | 2014 | NR | Y | NR | Y |
| Magge et al[56] | 2014 | Y | NR | NR | Y |
| Fukumoto et al[57] | 2014 | NR | NR | NR | Y |
| Alexander et al[58] | 2009 | Y | NR | Y | Y |
| van Iersel et al[59] | 2008 | Y | NR | Y | Y |
| Rizell et al[60] | 2008 | NR | NR | NR | NR |
| Pingpank et al[61] | 2005 | NR | NR | NR | NR |
| Alexander et al[62] | 2003 | Y | NR | NR | Y |
- Citation: Meng T, Li GQ, Dai MH. Isolated hepatic perfusion for unresectable hepatic malignancies: A systematic review and meta-analysis. World J Meta-Anal 2016; 4(5): 105-117
- URL: https://www.wjgnet.com/2308-3840/full/v4/i5/105.htm
- DOI: https://dx.doi.org/10.13105/wjma.v4.i5.105